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An essential step in the life cycle of the human immunodeficiency virus (HIV) is integration of a DNA copy
of the viral RNA into the genome of the infected cell. We show here that this step can be faithfully accomplished
in vitro by the enzymatic machinery of another retrovirus, Moloney murine leukemia virus (MoMLV).
Mini-HIV substrates, which are linearized plasmids with long terminal repeat sequences at their ends, were
incubated with cytoplasmic extracts of MoMLV-infected NIH 3T3 cells and target DNA. The MoMLV
integration apparatus carried out integration of the mini-HIV substrates correctly; the terminal nucleotides of
the viral substrate were removed, and a 4-base-pair duplication of the target DNA flanked the inserted viral
DNA (C. Shoemaker, S. P. Goff, E. Gilboa, M. Paskind, S. W. Mitra, and D. Baltimore, Proc. Natl. Acad.
Sci. USA 77:3932-3936, 1980). Our experiments show that the substrate sequence requirements for integration
in vitro were limited to a few nucleotides, as the similarity between HIV and MoMLV long terminal repeat ends
is minimal.
Integration of a double-stranded DNA copy of the viral
RNA into the genome of the infected cell is an essential step
in the life cycle of all retroviruses. Although much is still
unknown about the process of integration, the development
of cell-free integration assays has greatly contributed to the
understanding of this process. Cytoplasmic extracts from
NIH 3T3 cells infected with a mouse retrovirus, Moloney
murine leukemia virus (MoMLV), were shown to contain
MoMLV DNA that could be integrated into an exogenous
target DNA (1). By using this in vitro integration system, the
structure of the integration intermediate was elucidated (6).
The basic features of retroviral integration are the follow-
ing. After reverse transcription and second-strand DNA
synthesis, a linear, double-stranded DNA molecule with
blunt ends is formed. This DNA copy of the viral genome is
flanked by direct repeat sequences called long terminal
repeats (LTRs). At the outer edges of the two LTRs, short,
imperfect inverted repeats are present (for a review, see
reference 19). These sequences are sufficient for correct
integration (3, 4). The terminal nucleotides at each 3' end of
the blunt-ended DNA are then cleaved off, resulting in the
putative immediate precursor for integration (6, 13). This
cleavage reaction is probably executed by the viral integrase
protein, which is the only viral protein known to be required
for integration (2, 9, 13). The integrase is encoded by the 3'
part of the viral pol gene. A random sequence in the target
DNA is cut in a staggered pattern, giving rise to a 5'
overhang. The length of this staggered cut is virus specific
(20). The 5' ends of the target DNA are then joined to the
viral 3' OH ends. The last step in proviral integration is
repair of the gaps present in the intermediate. It is possibly
in this step that the terminal nucleotides at each proviral 5'
end are lost. The resulting provirus is now flanked by a short
direct duplication of the target DNA and terminates with
5'-TG --II--CA-3'.
* Corresponding author.
Recently, an assay was described in which cytoplasmic
extracts from MoMLV-infected NIH 3T3 cells (or disrupted
MoMLV particles) were capable of integrating exogenously
added mini-MoMLV DNA into target DNA (5). This assay
makes it possible to investigate whether the MoMLV inte-
gration machinery is also able to integrate other mini-
retroviral DNAs, such as mini-human immunodeficiency
virus (HIV) DNA. Although the general features of HIV and
MoMLV integration are probably similar, there are some
clear differences in the actual integration reactions. First, the
integrase proteins of HIV and MoMLV are not very similar;
there is less than 20% similarity on the amino acid level (7, 8,
17, 21). Second, the imperfect inverted repeats at the outer
edges of the LTRs, the only sequences necessary in cis for
correct integration, differ significantly between the two
retroviruses. The terminal 18 base pairs (bp) ofMoMLV are
aligned with the corresponding sequences from HIV-1 and
HIV-2. Only 7 of 18 bp at the HIV-1 U3 end match the
MoMLV sequence; at the HIV-2 U3 end, the match is 6 of 18
(Fig. 1B). At the U5 terminus, the match is 6 of 18 bp for
HIV-1 and 5 of 18 bp for HIV-2. Third, integrated MoMLV
proviruses are flanked by 4-bp directly repeated target DNA
duplications (18), whereas HIV proviruses are flanked by
5-bp target DNA duplications (12; C. Vink, M. Groenink, Y.
Elgersma, R. A. M. Fouchier, M. Tersmette, and R. H. A.
Plasterk, submitted for publication).
We tested the abilities of cytoplasmic extracts of
MoMLV-infected NIH 3T3 cells to use HIV-1 and HIV-2
DNA as substrates for correct integration. Extracts were
prepared as previously described (5). As an exogenous
substrate for integration, we first used a mini-MoMLV
plasmid in the in vitro system. The mini-MoMLV substrate
is a plasmid that can be digested with restriction endonucle-
ase NdeI, after which the ends of the plasmid are almost
identical to the termini of unintegrated viral DNAs within the
cytoplasm of MoMLV-infected cells. The only difference
between the mini-MoMLV DNA and wild-type MoMLV
DNA is the presence of a T instead of an A nucleotide at the
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A
MoMLV (pRP250-Ndel)
HIV- 1 (pRP 131 -Ndel)
HIV-2 (pRP255-[Adel)
HIV- 1 (pRP 1 37-Pvull)
Control (pRP268-Ndel)
U3 ernd
5' TATGAAAGAC,CCCACCTG - - // - - CAGCGGGGGTCTTTCA 3
3' ACTTTC'.TGGGGTGGAC - - // - - GTC;GCCCCCAGAAAGTAT 5'
TATGGAAGGGCTAATTCA - - // - - TGGA-AAATCTCTAGCA
ACCTTC'.-e-f:CGATTAAGT - - ACCTTTTAGAGATCGTAT
TATGI5,AAC,C,GATGTTTTA - - 1/ - - AGQ;AAAATCCCTAG'CA
ACCTTC.CCTACAAAAT - - // - - TCCTTTTAGGGATCGTAT
CTGGAAGGGCTAATTCA - - // - - TGGAAAATCTCTAGCAG
GAC,C,TTC'._,CGATTAAGT - - // - - ACCTTTTAGAGATCGTC
TATGGTGCAC_TCTCAGTA - - If - - GGTATTTCACACCGCA
ACCACGTGAGAGTCAT - - // - - CCATAAAGTGTGGCGTAT
U15 end
HIV- 1 C T G G A A G G G C T A A T T C A T G G A A A A T C T C T A G C A G
MoMLV A A T G AA A G A CC CCHC CHG-C A G|C G G G G G T C T T T C A T T
HIV-2 C T GGA A G G G A T T A A G GA A A AT C CC A G AG
FIG. 1. End sequences of plasmids and retroviruses. (A) The structures of the ends of the plasmid substrates (mini-retroviral DNAs) used
in this study. The mini-MoMLV substrate (pRP250) was constructed by cloning of the synthetic oligonucleotide 5'-AATTCAGG
TGGGGTCTTTCATATGAAAGACCCCCGCTGCA-3' and its complement (flanked by EcoRl and PstI cohesive ends) into the EcoRI and
PstI site of the vector PiAN7 (16). Cleavage of pRP250 by NdeI generates a linear mini-MoMLV with LTR terminal sequences at the ends,
which correspond to the U3 and U5 ends of MoMLV DNA (17), except for an A to T substitution at each 5' end. The plasmid pRP131
(mini-HIV-1) was constructed by cloning U3 and US LTR terminal sequences from plasmid pLTR (obtained from M. Alizon, Institut Pasteur,
Paris, France) into plasmid PiAN7. A NdeI restriction site was introduced at the junction between U3 and U5 sequences by site-directed
mutagenesis. In pRP131, the LTR sequences extend from the Hindlll site in the repeat region at position 77 in the HIV-1 sequence (21)
through U5 and U3 to the Sacl site at position 9129 in the repeat region. Digestion of pRP131 with NdeI generates a linear mini-HIV-1 with
LTR terminal sequences at the ends, which correspond to the U3 and U5 ends of HIV-1, except for the presence of the nucleotides AT at
the 5' ends, that are different in wild-type HIV-1 DNAs. Plasmid pRP137 is identical to pRP131 except for the presence of a PvuII site instead
of a NdeI site at the boundary between the U3 and U5 LTR terminal sequences. This PvuII site was introduced into the plasmid by
site-directed mutagenesis. In addition, pRP137 has a ScaI-PvuII fragment deleted from the U3 sequence. This fragment is located at position
8955 to 9075 in the HIV-1 sequence. Cleavage of plasmid pRP137 by PvuII generates a linear mini-HIV-1 with flush-ended termini. The
mini-HIV-2 substrate (pRP255) was constructed by ligation of the oligonucleotide 5'-AATTCTGTAAAACATCCCTTCCATATGCTAGG-
GATTTTCCTGCCTGCA-3' and its complement (flanked by EcoRI and PstI cohesive ends) in the vector PiAN7. Digestion of pRP255 with
NdeI generates a linear mini-HIV-2 with ends that are identical to the termini of the LTRs of HIV-2 except for the presence of the dinucleotide
AT at the 5' ends, which is different in wild-type HIV-2 DNA (7). The control plasmid pRP268 was constructed by cloning the
0.25-kilobase-pair EcoRI-BglIll fragment from pSVsupF (obtained from H. Klein, The Netherlands Cancer Institute, Amsterdam), containing
the amber suppressor tRNA gene supF, into the EcoRI and BamHI site of pUC18 (11). The plasmid was used in integration reactions after
linearization by NdeI. The ends of the linearized plasmid do not have obvious similarity to either HIV or MoMLV LTR termini. The
sequences that are in bold print should be lost during correct mini-proviral integration into the target DNA. For the MoMLV substrate, the
5' and 3' ends of both strands are indicated; the other constructs are drawn similarly. (B) Alignment of the LTR terminal sequences of
MoMLV with the ends of HIV-1 and HIV-2. Identical nucleotides are boxed. The HIV-1 sequence (21), the HIV-2 sequence (7), and the
MoMLV sequence (17) are shown.
5' ends of the mini-MoMLV substrate (Fig. 1). Such a
substitution, or addition of less than 5 bp to the termini, does
not seem to affect correct integration in vivo (13). The
mini-MoMLV DNA resembles the form of MoMLV DNA
that is supposed to be the immediate precursor for integra-
tion, because it lacks two nucleotides at both 3' ends that are
present in the expected full-length product of reverse tran-
scription and second-strand sythesis (6; Fig. 1).
As a target for integration, bacteriophage lambda Aam
Bam Sam DNA was included in the reaction mixture. After
incubation, the DNA was recovered from the reaction mix-
ture, and the lambda DNA was packaged in vitro. The
resulting phage were then plated on E. coli CA274 [sup'
lacZ(Am)]. Phage without insert are not able to grow on the
sup' host, since these phage contain amber mutations in
three genes that are essential for lytic growth in E. coli.
Upon integration of mini-retroviral DNAs in the phages,
however, the supF gene, which is present in the mini-
retroviral DNAs, is introduced into the phages. As a result,
these phages will form plaques on a sup' host, because the
amber mutations in the lambda DNAs can be suppressed. An
extra control for the presence of the supF gene in these
phages is that the plaques are blue in the presence of
isopropyl-,-D-thiogalactopyranoside and 5-bromo-4-chloro-
3-indolyl-p-D-galactopyranoside, since the host strain con-
tains a lacZ(Am) gene. The results of in vitro experiments
with mini-MoMLV DNA (pRP250) as a substrate are shown
in Table 1. Blue plaques were formed at a frequency similar
to those previously described (5). To test whether the
appearance of blue plaques in our assay was indeed the
result of correct retroviral integration, lambda DNAs from
two blue plaques were isolated and the junctions between
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TABLE 1. Integration' of mini-retroviral DNAs
Substrate No. of Total Integrationgrants plaques frequency (%)
MoMLV(pRP250, NdeI) 133 1.6 x 107 8.4 x 10-6 (100)
HIV-1(pRP131, NdeI) 75 1.6 x 108 4.7 x 10-7 (5.6)
HIV-2(pRP255, NdeI) 7 3.0 x 107 2.3 x 10-7 (2.7)
HIV-1(pRP137, PvuII) 0 1.8 x 108 <0.6 x 10-8 (<0.07)
Control(pRP268, NdeI) 0 9.2 x 107 <1.0 X l0-8 (<0.13)
HIV-1(pRP131, NdeI)b 0 3.4 x 107 <3.0 x 10-8 (<0.35)
a Integration reactions were carried out as previously described (5). Clone
4, a wild-type MoMLV-producing cell line derived from murine NIH 3T3
cells, was originally made by S. P. Goff (Columbia University, New York).
This cell line was obtained from R. Craigie (National Institutes of Health,
Bethesda, Md.). Clone 4 and uninfected NIH 3T3 cells were grown in
Dulbecco modified Eagle medium with 10% newborn calf serum. The prepa-
ration of cytoplasmic extracts from uninfected and MoMLV-infected NIH
3T3 cells was done as previously described (5). In each reaction, 0.26 pmol of
NdeI-linearized (pRP250, pRP255, pRP131, and pRP268) or PvuII-linearized
(pRP137) plasmid and 1.5 ,ug of lambda Aam Bam Sam concatemers (obtained
from L. Stubbs, Imperial Cancer Research Fund, London, England) were used.
Integration reactions were terminated by addition of 8 ,ul of 0.5 M EDTA (pH
8.0), 8 ,ul of 10-mg/ml Proteinase K (Merck & Co., Inc.), 10 p.l of 20%o sodium
dodecyl sulfate, and 224 ,ul of H20. After incubation at 45°C for 16 h, 100 p.1 of
1.5 M NaOAc (pH 7.0) was added and the samples were extracted with
buffer-saturated phenol and phenol-chloroform-isoamyl alcohol (25:24:1, vol/
vol/vol). The DNA was precipitated with ethanol, washed with 70%o ethanol,
and suspended in 6 pL. of 1 mM Tris hydrochloride (pH 8.0}0.05 mM EDTA.
The recovered DNA was packaged in an in vitro packaging system (Amersham
Corp.). Plating of the resulting phages on E. coli CA274 [supo lacZ(Am)] was
done as described by the manufacturers of the packaging system. To the plating
mixture, 0.4 mg of 5-bromo-4-chloro-3-indolyl-,3-D-galactopyranoside and 0.1
mg of isopropyl-p-D-thiogalactopyranoside per ml was added, and the mixture
was plated onto Luria-Bertani agar plates. Blue plaques were counted after
about 16 h of incubation at 37°C. Total phage titers were determined by plating
phage dilutions onto lawns of E. coli NM538 (supF). The columns show the
total numbers of plaques on the selective strain (from phage DNAs that have an
integrated miniretrovirus) and on the nonselective strain, the ratio between
these two (the integration frequency), and the relative integration frequency
(relative to the frequency for the mini-MoMLV substrate, expressed as a
percentage). Data were pooled from a duplicate set of experiments.
b Extract from uninfected NIH 3T3 cells.
MoMLV (pRP250-Ndel)
lambda DNA and integrated mini-MoMLV DNA were se-
quenced. The sequences are shown in Fig. 2. In both
recombinant phages, the mini-proviral DNAs terminate cor-
rectly with the sequence 5'-TG--II--CA-3' and are flanked by
a 4-bp directly repeated duplication of the target DNA,
which is characteristic of authentic MoMLV integration (18).
Target DNA duplication was checked by comparing the
duplicated sequence with the sequence of wild-type lambda
DNA (14).
For mini-HIV-i and mini-HIV-2 substrates, we used plas-
mids (pRP131 and pRP255) that comprise ends that, after
cleavage by NdeI, are identical to the termini of the putative
immediate precursors for integration of HIV-1 and HIV-2,
except for the presence of the dinucleotide AT at the 5' ends,
which is different in wild-type HIV-1 and HIV-2 DNAs. As
for the mini-MoMLV substrate, we assume that the crucial
aspect is the 3' terminal CA sequence at both ends that
ligates to the 5' overhanging target and that minor differ-
ences in the 5' overhanging termini of the mini-retroviral
DNAs are irrelevant. The results of the integration experi-
ments in which the mini-HIV substrates were used are listed
in Table 1. Both the mini-HIV-1 and the mini-HIV-2 plas-
mids that contain NdeI cohesive ends were integrated. The
frequency of integration of the mini-HIV-1 plasmid is about
20 times lower than the frequency of integration of the
mini-MoMLV substrate. The mini-HIV-2 plasmid was inte-
grated at a frequency that is approximately 40 times lower
than the integration frequency of the mini-MoMLV plasmid.
To check whether the blue plaques were the product of
correct retroviral integration, we isolated lambda DNAs
from two blue plaques from each integration reaction and
sequenced the junctions between the mini-HIV DNA and
lambda DNA. The HIV-1 and HIV-2 substrates were cor-
rectly integrated (Fig. 2); the terminal mini-HIV sequences
are 5'-TG--//--CA-3'. The integrated mini-HIV plasmids are
1. (15,868) GTGsGAAACTGA - - // - - TC.-AAAACC2A(CC
2. ( 19,477) TATACCTGTGA - - // - - TCACCTGCACT
HIV- 1 (pRP 131 -Ndel) -1. (33608) TT CGCTACTGG. - - // - - K-1CACTACCATC
. (30.374) CCTGAGAGT GG - - // - - QJi"AAGAGTTAA
HIV-2 (pRP255-Ndel) -1. (27,972) CG.CCTACCTGG'_ - - // - - (- YATACCTTTC
2. (29.392) AAAACATATGG - - // - - GCACATATAGA
UJ3 END-U5 EJD
X DNA l-MINI-PROVIRAL -i X DNA
DNA
FIG. 2. Sequences of the junctions between lambda DNA and integrated mini-proviral DNA. From two blue plaques from each integration
reaction, lambda DNAs were isolated by the method of Manfioletti and Schneider (10). The junctions between lambda DNAs and
mini-retroviral DNAs were directly sequenced by the dideoxy sequencing method (15) with the Sequenase system (United States Biochemical
Corp.). The sequencing primers used were 5'-CCACAGATCAAGGATAT-3' and 5'-ACTCTGGTAACTAGAGA-3' for mini-HIV-1 recom-
binants and 5'-TTACGTTGAGAAAGA-3' and 5'-AAACGCCAGCAACGC-3' for the other recombinants. The numbers in parentheses
indicate the positions of the first nucleotide of the sequences in the lambda DNA.
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flanked by 4-bp directly repeated target DNA duplications,
which is characteristic for MoMLV integration, and not by
5-bp target DNA duplications, which is characteristic for
HIV integration. This suggests that the length of the target
DNA duplication is determined by one or more virally
encoded proteins (in this study, from MoMLV) and not by
the DNA that is integrated (in this study, from HIV). The
integration of mini-retroviral DNAs in our assay is depen-
dent on MoMLV, since extracts from uninfected NIH 3T3
cells do not promote integration of the mini-HIV-1 plasmid
pRP131 (Table 1). Although the mini-HIV DNAs are inte-
grated at a lower frequency relative to the frequency of
integration of the mini-MoMLV substrate, it is clear from
our experiments that not all the nucleotides present at the
LTR termini of MoMLV are required for correct integration
(Fig. 1B). It is possible that only the nucleotides that are
similar among MoMLV and HIV-1 and HIV-2 (these nucle-
otides are boxed in Fig. 1B) are necessary for correct
integration. It cannot be excluded that for some of the
positions the conservation in sequence requirement is partial
(e.g., only purines are allowed) and that therefore some of
the positions not boxed in Fig. 1B may still be of importance.
To determine whether the cohesive ends that are gener-
ated by digestion with NdeI are possibly sufficient substrates
for integration, we tested a plasmid that does not contain any
viral sequences. We first cloned the supF gene into pUC18,
and the resulting plasmid, pRP268, was digested with NdeI
and used in the assay. No integration of this substrate was
observed (Table 1), indicating that NdeI cohesive ends are
not sufficient substrates for integration.
Another mini-retroviral substrate that we tested was a
mini-HIV-1 plasmid containing a PvuII restriction site at the
boundary between the U3 and U5 terminal sequences
(pRP137) (Fig. 1). When digested with PvuII, a G nucleotide
is present at the 3' ends of this plasmid. Prior to correct
integration, this nucleotide will have to be removed by the
integration machinery, thereby generating the 3' terminal
sequence CA-3'. No integration of substrate pRP137 was
detected. This is in agreement with the finding that the
MoMLV integration machinery is not able to integrate
blunt-ended mini-MoMLV substrates in vitro (5). A possible
explanation might be that the step in vivo preceding the
actual integration, the cutting off of the nucleotides beyond
the CA-3', is not carried out with sufficient efficiency on
exogenous DNA in this cell-free system and might depend
on the precise architecture of the endogenous integration
complex.
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